Updated 12 October 2017
NEW 2017 AAV CUSTOMERS: Please contact us at: Sales at GeneDetect.com for
assistance. Please click here for further
NEW 2017 GENE PROBE CUSTOMERS: Until early 2018 we will not be able to respond to new customer
enquiries except for new AAV production enquiries (see above). All current customers and projects remain fully supported and all
orders that have been accepted are being processed normally. Please see the Press Release below for further details. Thank you.
Contact page: Contact details
Click here for the Latest News
Current Product Catalog (1.18Mb
An Overview of in situ hybridization
In Situ hybridization Protocols
For a list of recent publications: Click
In situ hybridization blog (coming)
Track your package
GeneDetect® announces extension to its major alliance with leading European
Pharmaceutical and Diagnostics Company to perform contract gene
expression and biomarker validation assays. GeneDetect to receive
additional upfront payment and equity investment.
Friday February 10, 8:00am ET
Auckland (BUSINESS WIRE) February 10, 2012. GeneDetect (Sarasota, Florida and Auckland, New Zealand), a leading supplier of products and services to academic and government research institutions as well as pharmaceutical and biotechnology companies, announced today that it
has entered into a 5 year extension of its major alliance with a leading European Pharmaceutical
and Diagnostic company (THE COMPANY) to perform gene expression
and biomarker validation assays. The 5 year extension will last until at
least January 2018. GeneDetect will receive an additional upfront payment and equity investment
as part of the extended alliance.
The popular branded GeneDetect® and GreenStar hyperlabeled gene probe product ranges are used to measure gene expression in tissue samples.
"The GeneDetect® and GreenStar hyperlabeled gene probe product ranges are used worldwide everyday by researchers in leading research institutes and companies for this
purpose and are widely cited in the literature in leading scientific
journals" said GeneDetect Chairman and Chief Executive Officer Dr Paul E Hughes.
"It is a natural progression then that we work closely
with major Pharmaceutical companies on biomarker validation. While we
are focused on this major alliance we will ensure all current customers
and projects remain fully supported. However since this major alliance
will consume most of our production and screening capacity during this
time we will be unable to accept new customers and enquiries and we
apologize in advance for any inconvenience this may cause".
GeneDetect is a privately owned bioscience company with offices located in North America
(Sarasota, Florida) and the Asia-Pacific region (Auckland, New Zealand).
We develop, manufacture and market more than 4,000 products for the life sciences market. The company is globally focused with customers in over 40 countries and uses cutting edge e-commerce functionality to allow scientists worldwide to order its products online. Real-time pricing in multiple currencies, multi-currency billing, real-time credit card processing and a specialized ability to ship perishable goods to any location on the planet within 96 hours ensures a global customer base.
Web site: http://www.genedetect.com
About "THE COMPANY"
Headquartered in Basel, Switzerland, THE COMPANY is one of the world's leading research-focused healthcare groups in the fields of pharmaceuticals and
diagnostics and employs roughly 75,000 people in 150 countries. As a supplier of innovative products and services for the early detection, prevention, diagnosis and treatment of diseases, the Group contributes on a broad range of fronts to improving people's health and quality of life.
In 2006, the combined sales of the Pharmaceuticals and Diagnostics Division totaled
over 40.0 billion Swiss francs.
© 2000-2017 GeneDetect.com Ltd.
GeneDetect® GreenStarTM rAVETM, deprAVETM,
crAVETM, GenPepTM and OptiScriptTM are trademarks of GeneDetect.com Limited.